Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 1:36 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 385–408 of 835 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Intramuscular vaccine Clear all

Conditions: Tetanus, Acellular Pertussis, Diphtheria
Interventions: GSK Biologicals'Kinrix®, Merck and Company's MMRII, Merck and Company's Varivax; Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 4 Years to 6 Years
Enrollment: 478 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 11
States / cities: Antioch, California • Daly City, California • Hayward, California + 7 more

Conditions: Influenza
Interventions: GSK Biologicals' FluLaval®, Placebo (saline), GSK Biologicals' investigational H1N1 Influenza Vaccine - GSK2340274A, GSK Biologicals' investigational H1N1 Influenza Vaccine - GSK2340273A; Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 19 Years to 40 Years
Enrollment: 133 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 3
States / cities: Milford, Massachusetts • Salisbury, North Carolina • Winston-Salem, North Carolina

Conditions: Influenza, Human
Interventions: aQIV, Comparator QIV; Biological
Lead sponsor: Seqirus; Industry
Eligibility: 50 Years to 64 Years
Enrollment: 2,044 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 12
States / cities: Mobile, Alabama • Tempe, Arizona • Atlantis, Florida + 9 more

Conditions: Myeloproliferative Neoplasms
Interventions: VAC85135, Ipilimumab; Biological · Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 4
States / cities: Duarte, California • Tampa, Florida • Cleveland, Ohio + 1 more

Conditions: RENAL INSUFFICIENCY, CHRONIC, LIVER FAILURE, ACUTE, HEART DISEASE
Interventions: ProQuad; Biological
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 6 Months to 24 Months
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Influenza, Orthomyxoviruses, Myxovirus Infection
Interventions: Influenza virus vaccine - cell-based (2007-2008 Formulation), Influenza virus vaccine (2007-2008 Formulation); Biological
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 49 Years
Enrollment: 729 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2008
U.S. locations: 15
States / cities: Hoover, Alabama • Mobile, Alabama • Tucson, Arizona + 12 more

Conditions: HIV Infections, HIV Seronegativity
Interventions: APL 400-003; Biological
Lead sponsor: Wyeth-Lederle Vaccines; Industry
Eligibility: 18 Years to 60 Years
Healthy volunteers: Accepts healthy volunteers
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Asthma in Children, Vaccine Adverse Reaction, Vaccine Reaction, Asthma, Wheezing, Influenza
Interventions: Live Attenuated Influenza Vaccine (LAIV), Inactivated Influenza Vaccine (IIV); Biological
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 5 Years to 11 Years
Enrollment: 152 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2020
U.S. locations: 3
States / cities: Durham, North Carolina • Cincinnati, Ohio • Nashville, Tennessee

Conditions: Pneumococcal Infections
Interventions: V114, Prevnar 13™, PNEUMOVAX™23; Biological
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 302 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 4
States / cities: Orlando, Florida • West Palm Beach, Florida • Houston, Texas

Conditions: Tetanus, Acellular Pertussis, Diphtheria, Diphtheria-Tetanus-acellular Pertussis Vaccines
Interventions: Boostrix®, Decavac™; Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 65 Years and older
Enrollment: 1,332 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 24
States / cities: Tucson, Arizona • Los Angeles, California • DeLand, Florida + 21 more

Conditions: Meningococcal Infections, Meningitis
Interventions: Menactra®, Menomune®; Biological
Lead sponsor: Sanofi Pasteur, a Sanofi Company; Industry
Eligibility: 14 Years to 27 Years
Enrollment: 763 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2009
U.S. locations: 20
States / cities: Little Rock, Arkansas • Fountain Valley, California • Marietta, Georgia + 15 more

Conditions: Seasonal Influenza
Interventions: mRNA-1010, Licensed High-Dose Seasonal Influenza Vaccine; Biological
Lead sponsor: ModernaTX, Inc.; Industry
Eligibility: 65 Years and older
Enrollment: 200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 4
States / cities: Tucson, Arizona • Lenexa, Kansas • Louisville, Kentucky + 1 more

Conditions: Smallpox
Interventions: MVA Smallpox Vaccine, Placebo, Live vaccinia virus vaccine; Biological · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 38 Years
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2008
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Meningitis, Meningococcal Meningitis, Meningococcal Infections
Interventions: Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine, Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine; Biological
Lead sponsor: Sanofi Pasteur, a Sanofi Company; Industry
Eligibility: 10 Years to 55 Years
Enrollment: 3,344 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 89
States / cities: Birmingham, Alabama • Dothan, Alabama • Mobile, Alabama + 72 more

Conditions: Genital Herpes Simplex Type 2
Interventions: Matrix-M2, GEN-003, Placebo; Biological · Drug
Lead sponsor: Genocea Biosciences, Inc.; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 131 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 8
States / cities: Birmingham, Alabama • San Diego, California • San Francisco, California + 5 more

Conditions: Alopecia Areata
Interventions: PF-06651600, Tetanus and diphtheria toxoids and acellular pertussis (Tdap) vaccine, Meningococcal (groups A, C, W-135 and Y [ACWY]) oligosaccharide diphtheria CRM197 conjugate vaccine; Drug · Biological
Lead sponsor: Pfizer; Industry
Eligibility: 12 Years and older
Enrollment: 1,057 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 47
States / cities: Birmingham, Alabama • Beverly Hills, California • Irvine, California + 28 more

Conditions: Seasonal Influenza
Interventions: mRNA-1010, Placebo, Active Comparator; Biological
Lead sponsor: ModernaTX, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 885 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 21
States / cities: Phoenix, Arizona • Tempe, Arizona • Colton, California + 17 more

Conditions: Influenza, Human
Interventions: aQIV or aTIV, QIV or TIV; Biological
Lead sponsor: Seqirus; Industry
Eligibility: 65 Years and older
Enrollment: 38,769 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2026
U.S. locations: 111
States / cities: Birmingham, Alabama • Cullman, Alabama • Phoenix, Arizona + 96 more

Conditions: Melanoma (Skin Cancer), Advanced Melanoma, Metastatic Melanoma, Skin Cancer
Interventions: iSCIB1+, Nivolumab & Ipilimumab, Placebo; Biological · Drug · Other
Lead sponsor: Scancell Ltd; Industry
Eligibility: 18 Years and older
Enrollment: 550 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2032
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Herpes Zoster
Interventions: GSK Biologicals Herpes Zoster subunit (HZ/su) vaccine (GSK 1437173A); Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 65 Years and older
Enrollment: 430 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2017
U.S. locations: 32
States / cities: Huntsville, Alabama • Daly City, California • Los Gatos, California + 27 more

Conditions: Dengue, Dengue Fever, Dengue Hemorrhagic Fever
Interventions: CYD Dengue Vaccine, Japanese Encephalitis Vaccine; Biological
Lead sponsor: Sanofi Pasteur, a Sanofi Company; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 90 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Syracuse, New York

Conditions: Influenza, Influenza Vaccines
Interventions: Influenza A (H5N1) Virus monovalent vaccine, Saline placebo; Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 6 Months to 17 Years
Enrollment: 842 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2014
U.S. locations: 11
States / cities: Paramount, California • Sacramento, California • Newton, Kansas + 8 more

Conditions: HIV Infections
Interventions: AIDSVAX B/E Vaccine, DNA-HIV-PT123 Vaccine, Placebo for DNA-HIV-PT123, Placebo for AIDSVAX B/E; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 50 Years
Enrollment: 104 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 7
States / cities: San Francisco, California • New York, New York • Rochester, New York + 3 more

Conditions: Healthy
Interventions: VGX-3400X; Biological
Lead sponsor: Inovio Pharmaceuticals; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 2
States / cities: Overland Park, Kansas • Rockville, Maryland

Search by objective public record fields.

Immunogenicity and Safety of Kinrix + (Measles Mumps Rubella) MMR Vaccine With and Without Varicella Vaccine in Healthy Children 4-6 Years

Safety and Immune Response of Candidate H1N1 Influenza Vaccine GSK2340274A Following Seasonal Influenza Vaccination in Adults

A Clinical Study to Evaluate the Immunogenicity and Safety of an Adjuvanted Quadrivalent Influenza Vaccine Compared With a Licensed Quadrivalent Vaccine in Adults 50 to 64 Years of Age

A Study of VAC85135, a Neoantigen Vaccine Regimen, Concurrently Administered With Ipilimumab for the Treatment of Myeloproliferative Neoplasms

Safety and Efficacy of ProQuad® in Children 6-24 Month Being Evaluated for Solid Organ Transplant

Immunogenicity of a Split, Cell-Based, Inactivated, Trivalent Influenza Vaccine in Healthy Adult Subjects

Safety and Effects of Giving a New HIV Vaccine (GENEVAX-HIV) to HIV-Negative Volunteers

Safety of LAIV4 in Children With Asthma

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults Infected With Human Immunodeficiency Virus (HIV) (V114-018)

Evaluation of GlaxoSmithKline Biologicals' Boostrix® Vaccine in Comparison With Decavac™ Vaccine.

Persistence of Bactericidal Antibodies in Adolescents and Adults Who Had Received a Single Dose of Menactra® Vaccine

A Study of Updated mRNA Seasonal Influenza Vaccines

ACAM 3000 MVA at Harvard Medical School

Immune Lot Consistency, Immunogenicity, and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine

Evaluating New Formulation of Therapeutic HSV-2 Vaccine

Long-Term PF-06651600 for the Treatment of Alopecia Areata

A Study of mRNA-1010 Seasonal Influenza Vaccine in Healthy Adults

A Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an Adjuvanted Influenza Vaccine Compared to a Non-adjuvanted Influenza Vaccine in Adults ≥65 Years of Age

iSCIB1+ in Combination With Ipilimumab and Nivolumab as First-Line Treatment for Advanced Unresectable Melanoma

Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine (GSK1437173A) in Adults ≥ 65 Years of Age With and Without Zostavax® Vaccination at Least 5 Years Earlier

Immunologic Mechanisms of Immune Interference and/or Cross-Neutralizing Immunity After CYD Tetravalent Dengue Vaccine

Monovalent H5N1 Vaccine GSK1557484A in Children 6 Months to < 18 Years of Age

Evaluating the Safety and Immune Response to Different Combinations of the DNA-HIV-PT123 and AIDSVAX® B/E Vaccines in Healthy, HIV-Uninfected Adults

Study of VGX-3400X, H5N1 Avian Influenza Virus DNA Plasmid + Electroporation in Healthy Adults